Home » Stocks » ANIK

Anika Therapeutics, Inc. (ANIK)

Stock Price: $42.68 USD 0.48 (1.14%)
Updated May 13, 2021 4:00 PM EDT - Market closed
Market Cap 601.70M
Revenue (ttm) 129.35M
Net Income (ttm) -26.94M
Shares Out 14.34M
EPS (ttm) -1.89
PE Ratio n/a
Forward PE 106.38
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $42.68
Previous Close $42.20
Change ($) 0.48
Change (%) 1.14%
Day's Open 42.61
Day's Range 41.99 - 43.56
Day's Volume 138,878
52-Week Range 27.53 - 47.48

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Anika (ANIK) delivered earnings and revenue surprises of 225.00% and 5.87%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

BEDFORD, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard...

1 week ago - GlobeNewsWire

BEDFORD, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans ...

4 weeks ago - GlobeNewsWire

BEDFORD, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blancha...

1 month ago - GlobeNewsWire

BEDFORD, Mass., March 11, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blancha...

2 months ago - GlobeNewsWire

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Other stocks mentioned: DKL, HOLI, MELI, ROCK
2 months ago - Zacks Investment Research

Anika (ANIK) delivered earnings and revenue surprises of -1000.00% and -2.40%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Anika Therapeutics (NASDAQ:ANIK) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 72.09% year over year to $0.12, which beat t...

2 months ago - Benzinga

Completed Transformative Year with Q4 2020 Revenue Up 10% Year-Over-Year, Full Year 2020 Revenue up 14% Well Positioned for Growth in 2021

2 months ago - GlobeNewsWire

BEDFORD, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company that creates and delivers meaningful advancements in early intervention ort...

3 months ago - GlobeNewsWire

Just like selecting good and undervalued stocks on a regular basis can make you rich, identifying and proactively getting rid of toxic stocks is also crucial to maximizing portfolio returns.

Other stocks mentioned: LAUR, NUAN, VREX
4 months ago - Zacks Investment Research

Anika Therapeutics (ANIK) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

4 months ago - Zacks Investment Research

Anika Therapeutics, Inc. (ANIK) CEO Cheryl Blanchard on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Anika Therapeutics, Inc.'s (ANIK) CEO Cheryl Blanchard on Q3 2020 Results - Quick Version Earnings Call Transcript

6 months ago - Seeking Alpha

Anika (ANIK) delivered earnings and revenue surprises of -462.50% and -1.63%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Revenue Increased 7% Year-over-Year to $ 31.7 Million Repaid $25 M illion of Outstanding Credit Facility Continued Expansion of Joint Preservation Product Portfolio

6 months ago - GlobeNewsWire

Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

BEDFORD, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company that creates and delivers meaningful advancements in early intervention ort...

6 months ago - GlobeNewsWire

System designed to alleviate pain and restore function and mobility of the wrist joint System designed to alleviate pain and restore function and mobility of the wrist joint

6 months ago - GlobeNewsWire

ANIK vs. ILMN: Which Stock Is the Better Value Option?

Other stocks mentioned: ILMN
7 months ago - Zacks Investment Research

Board Chair Joseph Bower, D.B.A. announces intention not to stand for re-election at 2021 Annual Meeting Jeffery Thompson succeeds Dr. Bower as Chair of the Board

8 months ago - GlobeNewsWire

ANIK vs. NEO: Which Stock Is the Better Value Option?

Other stocks mentioned: NEO
8 months ago - Zacks Investment Research

BEDFORD, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation, restoration and regenerative solutions company with products acro...

8 months ago - GlobeNewsWire

ANIK vs. ALKS: Which Stock Is the Better Value Option?

Other stocks mentioned: ALKS
8 months ago - Zacks Investment Research

Seasoned financial executive brings broad medical device industry experience and track record of value creation Seasoned financial executive brings broad medical device industry experience and track rec...

9 months ago - GlobeNewsWire

ANIK vs. ALKS: Which Stock Is the Better Value Option?

Other stocks mentioned: ALKS
9 months ago - Zacks Investment Research

Anika Therapeutics, Inc.'s (ANIK) CEO Cheryl Blanchard on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Anika Therapeutics: After A Stormy Period, Orthopedic Specialist Looks Set Fair

9 months ago - Seeking Alpha

Anika (ANIK) delivered earnings and revenue surprises of 142.86% and 83.37%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

Increased Total Revenue 1% Year-over-Year to $30.7 Million Accelerated the Commercial Integration of Parcus Medical and Arthrosurface Organizations Launching Seven FDA-Cleared Orthopedic and Sports Me...

9 months ago - GlobeNewsWire

Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

Innovative Products Designed to Meet Needs of Surgeons and their Patients in Joint Preservation and Restoration Procedures Innovative Products Designed to Meet Needs of Surgeons and their Patients in J...

9 months ago - GlobeNewsWire

BEDFORD, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation, restoration and regenerative solutions company with products acros...

9 months ago - GlobeNewsWire

Sylvia Cheung to Step Down in August 2020

11 months ago - GlobeNewsWire

Anika Therapeutics, Inc.'s (ANIK) CEO Cheryl Blanchard on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Anika (ANIK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 year ago - Zacks Investment Research

Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

BEDFORD, Mass., April 08, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its pr...

1 year ago - GlobeNewsWire

A recent acquisition and a new product launch held back earnings, but should be beneficial over the long term.

1 year ago - The Motley Fool

Anika Therapeutics, Inc. (ANIK) CEO Cheryl Blanchard on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Anika (ANIK) delivered earnings and revenue surprises of 4.88% and 7.75%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

BEDFORD, Mass., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that Dr. Cheryl Blanchard, a member of the Company’s Board of Directors since August 2018, h...

1 year ago - GlobeNewsWire

Transaction Accelerates Anika’s Revenue Growth, Broadens Joint Preservation and Restoration Product Portfolio, Enhances Commercial Capabilities and Expands Pipeline Transaction Accelerates Anika’s Reven...

1 year ago - GlobeNewsWire

BEDFORD, Mass., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK) announced today with great sadness that Joseph Darling, its President and Chief Executive Officer, passed away...

1 year ago - GlobeNewsWire

Transaction Accelerates Anika’s Revenue Growth, Broadens Joint Preservation and Restoration Product Portfolio, Enhances Commercial Capabilities and Expands Pipeline Transaction Accelerates Anika’s Reven...

1 year ago - GlobeNewsWire

Biotech Stock Outlook: M&A Activity Retains Growth Streak

Other stocks mentioned: ACAD, ALXN, GILD, INCY, REGN, VRTX
1 year ago - Zacks Investment Research

Possibility of at least an interim trade deal between the largest trading countries of the world boosted investors' confidence on risky assets like equities.

Other stocks mentioned: BDSI, CROX, PLXS, UFI
1 year ago - Zacks Investment Research

Does Anika Therapeutics (ANIK) have what it takes to be a top stock pick for momentum investors? Let's find out.

1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Anika Therapeutics, Inc. (ANIK).

1 year ago - Zacks Investment Research

Anika Therapeutics Inc. (ANIK) CEO Joseph Darling on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

About ANIK

Anika Therapeutics, Inc., together with its subsidiaries, operates as a joint preservation company that in the United States, Europe, and internationally. The company's joint pain management products include Monovisc and Orthovisc, which are single- and multi-injection, hyaluronic acid (HA)-based viscosupplements to provide pain relief from osteoarthritis (OA) conditions; Cingal, a novel, third-generation, single-injection OA product consisting of its proprietary cross-linked HA material combined with a steroid to provide short- and long-term p... [Read more...]

Industry
Biotechnology
IPO Date
Apr 29, 1993
CEO
Joseph Darling
Employees
277
Stock Exchange
NASDAQ
Ticker Symbol
ANIK
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for ANIK stock is "Buy." The 12-month stock price forecast is 48.00, which is an increase of 12.46% from the latest price.

Price Target
$48.00
(12.46% upside)
Analyst Consensus: Buy